Proteins and Peptides

05 Jan 2022 Allena Pharmaceuticals Provides Clinical and Corporate Update
04 Jan 2022 Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers
29 Dec 2021 Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease
29 Dec 2021 Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of imlifidase in highly sensitized kidney transplant patients
21 Dec 2021 Lannett announces submission of investigational new drug (IND) application for biosimilar insulin glargine
16 Dec 2021 Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis
15 Dec 2021 Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
15 Dec 2021 ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
15 Dec 2021 First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001
12 Dec 2021 Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting
08 Dec 2021 SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
07 Dec 2021 Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18
07 Dec 2021 Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021
07 Dec 2021 Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
04 Dec 2021 European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease
04 Dec 2021 Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications
03 Dec 2021 Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML
30 Nov 2021 Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease
22 Nov 2021 Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide
16 Nov 2021 Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19
14 Nov 2021 Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting
14 Nov 2021 Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
14 Nov 2021 Asher Bio Announces New Preclinical Data Demonstrating Best-in-Class Potential of AB248, Its Lead Cis-Targeted Il-2 Immunotherapy
14 Nov 2021 U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera
12 Nov 2021 SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up